Skip Menu

Return to Skip Menu

Main Content

Biotechnology News - Yahoo

Syndicate content Yahoo! Finance
The latest news on the Biotechnology industry from Yahoo! Finance
Updated: 1 hour 27 min ago

BioMarin shares rise on Citi upgrade to 'Buy' (AP)

1 hour 27 min ago
Shares of BioMarin Pharmaceutical Inc. rose Friday after Citi upgraded the stock based on the sales potential for its three approved treatments, its early-stage development products and healthy cash position.

Oppenheimer takes cautious view on ViroPharma (AP)

1 hour 27 min ago
Oppenheimer & Co. started coverage on ViroPharma Inc. Friday with a "Perform" rating, taking a cautious position on the company over concern that competitors for its core products are closer to reaching the market.

Gilead Sciences, Microsoft: Money Flow Leaders (GILD, MSFT) (at The Wall Street Journal Online)

1 hour 27 min ago
Gilead Sciences, Microsoft: Money Flow Leaders Markets Data Center: Money Flow Leaders.

BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer (PR Newswire)

1 hour 27 min ago
BioMarin Pharmaceutical Inc. today announced that Dr. Emil Kakkis, its Chief Medical Officer will retire from the company on February 27, 2009.

Heska to Present at New York Society of Security Analysts' 12th Annual Biotech and Specialty Pharma Conference (PR Newswire)

1 hour 27 min ago
Heska Corporation today announced it will present at the New York Society of Security Analysts' 12th Annual Biotech and Specialty Pharma Conference on December 2, 2008 at 1177 Avenue of the Americas, 2nd Floor in New York, NY.

Exelixis Announces December 2 Webcast of Presentation at the Piper Jaffray 20th Annual Health Care Conference (Business Wire)

1 hour 27 min ago
SOUTH SAN FRANCISCO, Calif.----Exelixis, Inc. announced today that George A. Scangos, PhD, President and Chief Executive Officer of Exelixis, will present at the Piper Jaffray 20th Annual Health Care Conference at 11:00 a.m.

Dyax drug candidate gets FDA priority review (AP)

1 hour 27 min ago
Dyax Corp. said Friday the Food and Drug Administration is giving priority review to the biotechnology company's developing treatment for a genetic condition that can lead to dangerous swelling.

BioTime Inc. Announces Third Quarter 2008 Financial Results (Business Wire)

1 hour 27 min ago
ALAMEDA, Calif.----On November 19, 2008 BioTime, Inc. reported financial results for the quarter ended September 30, 2008.

NPS Pharmaceuticals to Present at Piper Jaffray Health Care Conference (Business Wire)

1 hour 27 min ago
BEDMINSTER, N.J.----NPS Pharmaceuticals, Inc. announced today that Francois Nader, M.D., president and chief executive officer, is scheduled to present at the 20th Annual Piper Jaffray Health Care Conference in New York on Wednesday, December 3, 2008 at 12:00 p.m.

Invitrogen and Applied Biosystems Complete Merger (Business Wire)

1 hour 27 min ago
CARLSBAD, Calif.----Invitrogen Corporation and Applied Biosystems Inc. today announced the successful completion of their merger transaction. The new company will be named Life Technologies Corporation and will be traded on the NASDAQ Global Select Market under the ticker symbol "LIFE" beginning November 24, 2008.

Pharmaceuticals Industry (Zacks.com)

1 hour 27 min ago
Although not completely recession-proof, there are several key underlying characteristics that make the industry a good place to hide out in a down market.

CTI chief learns hard lessons from merger (at FT.com)

1 hour 27 min ago
The chief executive of Seattle-based Cell Therapeutics says he has learnt some tough lessons from his experience of integrating a pair of US and Italian biotechnology companies.

FDA Accepts Filing and Grants Priority Review for DX-88 for Hereditary Angioedema (Business Wire)

1 hour 27 min ago
CAMBRIDGE, Mass.----Dyax Corp. announced today that the U.S. Food and Drug Administration has accepted for filing the Companyâ??s Biologics License Application for DX-88 for the treatment of acute attacks of hereditary angioedema and has designated the application for Priority Review.